Search Results

#ASH18: Beating AML

Sunday marked a significant milestone for The Leukemia & Lymphoma Society (LLS) and the patients we help. Here at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, a conference attended by more than 30,000 scientists from around the world, we unveiled the first results from our groundbreaking precision medicine Beat AML Master Clinical Trial. To date, more than 356 patients have been screened for this trial.

NBA Rookie Honors Late Coach by Donating Car to LLS

Thanks to Karl-Anthony Towns, The Leukemia & Lymphoma Society (LLS) will be getting a brand new Kia!

The NBA awarded the 2015-16 Kia NBA Rookie of the Year Award to Karl-Anthony Towns of the Minnesota Timberwolves on May 16 by handing him keys to a brand new Sorento CUV.

Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.

Support at Your Fingertips: Try a Discussion Board

Having cancer can be a lonely experience, and it’s not always so easy to find others with a similar diagnosis. Even if you could, you might not always want to talk about everything face to face.

Sometimes an online discussion board is just what you need.

Hydroxyurea

Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.

Methotrexate

Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.

Alemtuzumab

Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).

Bosutinib

Bosutinib is FDA approved for the treatment of

Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.

Decitabine and cedazuridine

Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

Avapritinib

Ayvakit® is indicated for the treatment of

When The Time Comes: Katie & Phil’s Story

Breaking Down Barriers in Blood Cancer Care

All patients deserve quality cancer care that's within reach

LLS and volunteers cheer California laws promoting health equity

BURLINGTON STORES AND THE LEUKEMIA & LYMPHOMA SOCIETY CONTINUE THEIR PARTNERSHIP IN THE FIGHT AGAINST BLOOD CANCER

The Leukemia & Lymphoma Society Names Lore Gruenbaum, Ph.D., New Chief Scientific Officer

Research Funded by The Leukemia & Lymphoma Society Among Highlights at Annual American Society of Hematology

Louis J. DeGennaro, Ph.D., Named President and Chief Executive Officer of The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society’s Light The Night Events Lead the Charge Against Blood Cancer

The Leukemia & Lymphoma Society Awards $65 Million in New Funding for Blood Cancer Research

The Leukemia & Lymphoma Society Honors Five Outstanding Blood Cancer Scientists with 2023 Awards

The Leukemia & Lymphoma Society’s Illinois Chapter Announces Local 2020 Students of the Year Winner

Suggested Reading - Childhood Leukemia Guide for Families, Friends and Caregivers, 5th ed.

By Nancy Keene
Childhood Cancer Guides, 2018, 496 pages
ISBN: 978-1-941089-04-0

This most complete parent guide provides accurate and understandable medical information about leukemia and the various treatment options, as well as day-to-day practical advice on how to cope with procedures, hospitalization, family and friends, school, social and financial issues, and communicating with healthcare providers. Reviewed by distinguished experts in pediatric oncology, Childhood Leukemia includes practical and poignant stories from more than 175 parents, children with leukemia, and their siblings. This book helps families cope––one day at a time.

For more information click here

Audience

Adults

Subject

Coping